Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 218

1.

Inhibitory effects of azelnidipine tablets on morning hypertension.

Kario K, Sato Y, Shirayama M, Takahashi M, Shiosakai K, Hiramatsu K, Komiya M, Shimada K.

Drugs R D. 2013 Mar;13(1):63-73. doi: 10.1007/s40268-013-0006-8.

2.

Study of sustained blood pressure-lowering effect of azelnidipine guided by self-measured morning and evening home blood pressure: subgroup analysis of the At-HOME study.

Kario K, Uehara Y, Shirayama M, Takahashi M, Shiosakai K, Hiramatsu K, Komiya M, Shimada K.

Drugs R D. 2013 Mar;13(1):75-85. doi: 10.1007/s40268-013-0007-7.

3.
5.

The effects of the L/N-type calcium channel blocker (cilnidipine) on sympathetic hyperactive morning hypertension: results from ACHIEVE-ONE.

Kario K, Ando S, Kido H, Nariyama J, Takiuchi S, Yagi T, Shimizu T, Eguchi K, Ohno M, Kinoshita O, Yamada T.

J Clin Hypertens (Greenwich). 2013 Feb;15(2):133-42. doi: 10.1111/jch.12042. Erratum in: J Clin Hypertens (Greenwich). 2013 Aug;15(8):610.

6.

Hemodynamic influences of azelnidipine, a novel calcium channel blocker, on cerebral circulation in hypertensive patients with ischemic white matter lesions.

Kimura Y, Kitagawa K, Oku N, Kajimoto K, Kato H, Tanaka M, Sakaguchi M, Hougaku H, Sakoda S, Hatazawa J.

Hypertens Res. 2008 Dec;31(12):2147-54. doi: 10.1291/hypres.31.2147.

PMID:
19139604
7.

Plasma renin activity and aldosterone concentration are not altered by the novel calcium channel antagonist, azelnidipine, in hypertensive patients.

Kondo T, Goto R, Sonoda K, Yasuda T, Ono K, Takaki Y, Yatsuda R, Miyamura N, Araki E.

Intern Med. 2010;49(7):637-43.

9.

Regular alcohol drinking is a determinant of masked morning hypertension detected by home blood pressure monitoring in medicated hypertensive patients with well-controlled clinic blood pressure: the Jichi Morning Hypertension Research (J-MORE) study.

Ishikawa J, Kario K, Eguchi K, Morinari M, Hoshide S, Ishikawa S, Shimada K; J-MORE Group..

Hypertens Res. 2006 Sep;29(9):679-86. Erratum in: Hypertens Res. 2007 Feb;30(2):203.

PMID:
17249523
10.

Comparison of Azelnidipine and Trichlormethiazide in Japanese Type 2 Diabetic Patients with Hypertension: The COAT Randomized Controlled Trial.

Takihata M, Nakamura A, Kondo Y, Kawasaki S, Kimura M, Terauchi Y.

PLoS One. 2015 May 4;10(5):e0125519. doi: 10.1371/journal.pone.0125519.

11.
13.

Pharmacological profiles and clinical effects of azelnidipine, a long-acting calcium channel blocker.

Sada T, Saito H.

Nihon Yakurigaku Zasshi. 2003 Dec;122(6):539-47. Review.

PMID:
14639008
14.

Azelnidipine.

Wellington K, Scott LJ.

Drugs. 2003;63(23):2613-21; discussion 2623-4. Review.

PMID:
14636080
15.

Artist® tablets (carvedilol) for hypertensive patients in Japan: results of a drug use survey.

Mori Y, Nishikawa Y, Iizuka T, Zenimura N, Matsumoto T, Hiramatsu K, Komiya M.

Drugs R D. 2011;11(2):171-90. doi: 10.2165/11592450-000000000-00000.

16.
17.

Effects of new calcium channel blocker, azelnidipine, and amlodipine on baroreflex sensitivity and ambulatory blood pressure.

Eguchi K, Tomizawa H, Ishikawa J, Hoshide S, Fukuda T, Numao T, Shimada K, Kario K.

J Cardiovasc Pharmacol. 2007 Jun;49(6):394-400.

PMID:
17577104
18.

Olmesartan medoxomil and azelnidipine therapy in patients with hypertension and chronic kidney disease in Japan.

Saito I, Kushiro T, Zenimura N, Matsushita Y, Sagawa K, Hiramatsu K, Yamaguchi F.

J Nephrol. 2012 Sep-Oct;25(5):699-708. doi: 10.5301/jn.5000043.

PMID:
22020401
20.

Prevalence of Masked Hypertension in Subjects Treated with Antihypertensive Drugs as Assessed by Morning versus Evening Home Blood Pressure Measurements: the J-HOME study.

Obara T, Ohkubo T, Asayama K, Kikuya M, Metoki H, Inoue R, Komai R, Murai K, Hashimoto J, Totsune K, Imai Y; J-Home Study Group..

Clin Exp Hypertens. 2008 Apr;30(3):277-87. doi: 10.1080/10641960802071018.

PMID:
18425707

Supplemental Content

Support Center